AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms

Access the webinar recording

Thanks for your interest in our recent AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording.

Our approach

Initiating antibody discovery with broad diversity of in vivo models increases the probability of successfully identifying therapeutic antibodies against challenging targets. Alloy Therapeutics has developed novel transgenic animal strains for fully human antibody discovery, including strains with Lambda light chains to increase structural diversity and Hyperimmune strains to increase the number of antigen-specific B-cells and enhanced IgG class switching.

Schedule a consultation

Webinar Speakers

Tom Vincent

Senior Director, Antibody Technology

Targeting GPCRs with Alloy Antibody Discovery Services

Access the white paper

Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.

G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.

Keyway TCR Mimic Discovery Webinar

Access the webinar recording

I’d like more material about Keyway TCR Discovery

Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:

1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

Upon filling out this form, you will receive an email with a link to the webinar recording.